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Abstract
Objective: A study is made of the clinical course of patients with episodic cluster headache following the injection 
of corticosteroids in the proximity of the sphenopalatine ganglion of the affected side. 
Study Design: A retrospective observation study was made corresponding to the period between 2006 and 2010. 
Patients with episodic cluster headache received corticosteroid infiltrations in the vicinity of the sphenopalatine 
ganglion. Data were collected to assess the clinical course, quantifying pain intensity and quality of life. A total of 
23 patients (11 women and 12 men) with a mean age of 50.4 years (range 25-65) were included. Forty percent of the 
patients had undergone dental extractions in the quadrant affected by the pain, before the development of episodic 
cluster headache, and 37.8% underwent extractions in the same quadrant after appearance of the headache.
Results: Most of the patients suffered 1-3 attacks a day, with a duration of pain of between 31-90 minutes. The 
mean pain intensity score during the attacks at the time of the first visit was 8.8 (range 6-10), versus 5.4 (range 3-9) 
one week after the first corticosteroid injection. On the first visit, 86.9% of the patients reported unbearable pain, 
versus 21.7% after one week, and a single patient after one month.
Conclusions: The evolution of episodic cluster headache is unpredictable and variable, though corticosteroid ad-
ministration clearly reduces the attacks and their duration.
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Introduction
Episodic cluster headache (ECH) is characterized by 
unilateral attacks of pain in the upper premolar, peri-
orbital or temporal region, or in a combination of these 
locations, accompanied by ipsilateral conjunctival in-
jection, tearing, nasal congestion, perspiration of the 
affected side of the face, miosis, and homolateral palpe-
bral ptosis and edema. The attacks typically last 15 to 
180 minutes, and patients experience one or several 
attacks a day in the course of an outbreak of variable 
duration (weeks or months). The episodic presentation 
of the disorder is characterized by periods of complete 
remission (1,2). 
The etiopathogenesis of cluster headache is unclear, but 
appears to involve the activation of parasympathetic 
nerve structures in the sphenopalatine ganglion, which 
would explain many of the associated symptoms. In ad-
dition, activation of the ipsilateral hypothalamic gray 
matter could explain the typical circadian and circuman-
nual periodicity of the disorder (3). The sphenopalatine 
ganglion is the largest peripheral parasympathetic gan-
glion with connections to the sensory fibers and plexus 
of the internal carotid artery (4). The sensory and motor 
fibers and autonomic components are implicated in the 
physiopathology ECH (5). In the case of chronic head-
aches resistant to drug therapy, sphenopalatine ganglion 
block has been shown to offer some efficacy (3). The most 
common indications of sphenopalatine ganglion block 
include cluster headache and atypical facial pain (6). 
Treatment efficacy in cluster headache is difficult to 
evaluate, due to the great variations in the duration of 
each outbreak. Until improved knowledge is gained of 
the etiopathogenic mechanisms of cluster headache, the 
most useful treatment option is to counter one of the 
phenomena giving rise to the pain: arterial vasodilata-
tion. The management of ECH includes three treatment 
modalities: non-pharmacological (general measures 
and patient education), pharmacological (abortive drugs 
and preventive treatment) and surgical.
Abortive therapy aims to arrest individual attacks, and 
comprises the use of subcutaneous sumatriptan, ergot-
amine and oxygen inhalation (2,7). The aim of preven-
tive treatment is to shorten the duration of ECH and 
reduce the frequency of the attacks. In this case corti-
costeroids, verapamil, lithium, topiramate and greater 
occipital nerve block have been found to be effective 
(2,8,9). There is clinical evidence of the efficacy of cor-
ticosteroids in application to cluster headache (10). In ef-
fect, these drugs quickly improve the attacks in both the 
chronic and episodic forms of the disease, as a result of 
their central and peripheral antiinflammatory effects (11).
The present study evaluates the clinical course of pa-
tients with episodic cluster headache following the in-
jection of corticosteroids in the proximity of the sphen-
opalatine ganglion of the affected side.
Material and Methods
Patient selection 
A retrospective, descriptive and follow-up clinical case 
study was carried out between the years 2006 and 2010 
in patients with episodic cluster headache seen in a Uni-
versity oral surgery clinic. Episodic cluster headache 
(ECH) was diagnosed according to the criteria of the 
International Headache Society (HIS) (1): 1) severe or 
very severe unilateral pain affecting the orbital, supraor-
bital, temporal and/or upper maxillary regions, with a 
duration of 15 to 180 minutes; 2) headache accompanied 
by signs of autonomic dysfunction; 3) pain character-
ized by a frequency of between one attack every two 
days and 8 attacks a day; and 4) pain not attributable to 
any other disease. 
The following patient inclusion criteria were used: 1) 
attacks of cluster headache; 2) treatment with corticos-
teroid injections close to the sphenopalatine ganglion; 
and 3) a minimum follow-up of 12 months. The criteria 
used for corticosteroid injection were: 1) patients with 
active ECH even after the start of some other treatment; 
and 2) the absence of general contraindications to cor-
ticosteroid injection (diabetes or gastrointestinal ulcer). 
Episodic cluster headache was finally diagnosed in 26 
patients; three patients were excluded due to a clack 
of the required minimum 12 months of follow-up. We 
thus included 23 patients with ECH, with a mean age of 
50.4 years (range 25-65) (11 women and 12 men). Forty 
percent of the patients had undergone dental extractions 
in the quadrant affected by the pain, before the devel-
opment of episodic cluster headache, and 37.8% under-
went extractions in the same quadrant after appearance 
of the headache.
Data collection and follow-up of pain
The following data were collected: patient age and gen-
der, dental surgical treatment in the affected quadrant 
before and after appearance of the pain, and charac-
teristics of the pain: location, frequency (number of at-
tacks/day), duration of the attacks (minutes), and inten-
sity (based on a 10-cm visual analog scale (VAS), where 
10 corresponds to maximum pain intensity).
Patient disability and quality of life were evaluated by 
means of a clinical scale scored from 0-6, where 1 = 
no pain, 2 = mild pain (pain attacks some days of the 
month, with practically no impact upon quality of life), 
3 = bothersome pain (pain attacks some days of the 
month, causing concern, but with almost normal daily 
life activities), 4 = moderate pain (occasional daily at-
tacks or pain at some point during the day, preventing 
normal live), 5 = important pain (frequent daily attacks 
seriously affecting quality of life) and 6 = terrible pain 
(very frequent daily attacks very seriously affecting 
quality of life). We documented the days with pain cor-
responding to the period from the last outbreak to the 
time of the first visit (less than 7 days, 7-15 days and 
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over 15 days), and the autonomic manifestations associ-
ated with the pain.
The patients received corticosteroid injections in the 
proximity of the sphenopalatine ganglion of the affect-
ed side. In the case of more than one attack a day, we 
prescribed prophylactic treatment in the form of 2 mg of 
ergotamine via the oral route. In patients with a single 
daily attack of pain we only administered corticoster-
oids in the vicinity of the sphenopalatine ganglion. One 
infiltration a week was carried out during four weeks, 
and in the absence of pain throughout the week, no fur-
ther infiltrations were made. The possible side effects of 
the medication were recorded.
Injection technique
Truncal superior posterior dental nerve block was carried 
out using an auto-aspirating metal syringe and long needle 
Results
In 47.8% of the patients the pain was located in the 
premolar region, irradiating towards the orbit and tem-
poral region; in 39.1% of the cases the pain was located 
in the periorbital region, irradiating towards the temple; 
and in 13% of the subjects the pain was diffusely lo-
cated in the upper maxillary, temporal and mandibular 
region. The pain affected the right side in 56.5% of the 
patients, and the left side in 43.5%. Most of the subjects 
experienced between 1-3 attacks/day, and in most cases 
the attacks lasted 31-60 minutes (Table 1).
The pain had been present for under 10 days in 26% of 
the patients, between 11-20 days in 17.3%, between 21-
40 days in 13%, between 41-60 days in 17.3%, and for 
over 60 days in 26% of the patients. The mean intensity 
of pain on the first visit was 8.8 (range 6-10). The clini-
Mean 
intensity
No. attacks/day Duration
0 1 2-3 >3 0 m 1-30 m 31-60 m 1-2 h >2 h 
First visit 8.8 (6-10) - 8 11 4 -       5 11 4 3 
After
treatment 
5.4 (3-9) 6 11 6 0 6      11   5 1 - 
Table 1. Number of attacks and pain intensity and duration before treatment.
m: minutes
h: hours
(25-30 mm) with 4% articaine and adrenalin 1:100,000 (In-
ibsa®, Lliça de Vall, Barcelona, Spain). The injection site 
was on the posterolateral surface of the upper maxilla, at 1 
cm above and behind the last molar. The needle penetrated 
mesial to the upper first molar and was advanced towards 
the zygomatic process until reaching the vestibular depth 
of the upper second molar, directing inwards, upwards and 
backwards to form an angle of approximately 45 degrees 
with respect to the upper occlusal plane. The anesthetic so-
lution was slowly injected after negative aspiration.
While waiting a few minutes for the anesthetic solu-
tion to exert its effect, the empty anesthetic carpule was 
filled with 40 mg of triamcinolone acetonide (Trigon 
Depot®, Bristol-Meyers Squibb, Madrid, Spain), and the 
full contents of the carpule were injected into the vicin-
ity of the sphenopalatine ganglion (in the same way as 
the anesthetic block).
Clinical course 
The patient clinical course and improvement were as-
sessed according to the pain intensity (on the first visit, 
every week after infiltration, and after one month) and 
the clinical disability scale (on the first visit, after 1, 3 
and 6 months, and after one year). The duration of the 
outbreak was classified as follows: less than 10 days, 11-
20 days, 21-40 days, 41-60 days and over 60 days.
cal scale on the first visit showed patient disability to be 
moderate in 13% of the case, important in 56.6%, and 
terrible in 30.4%. The pain was accompanied by vegeta-
tive manifestations in 73% of the cases – particularly 
nasal secretion, tearing and reddening in the affected 
zone.
Corticosteroid treatment involved a single infiltration 
in 26% of the cases, two injections in 52.1%, and three 
injections in 21.7%. A total of 73.9% of the patients re-
ceived additional drug treatment.
The data relating to the number and duration of the at-
tacks after the treatment received is reported in (Table 1). 
One week after the first injection, the mean pain inten-
sity score was 5.4 (range 3-9), while one week after the 
second injection the mean score was 4.4 (range 2-9). In 
turn, after the third injection the mean pain intensity 
was 4.6 (range 3-9), versus 2.8 (range 0-7) after one 
month. Table 2 describes the evolution of patient disa-
bility. On the first visit, 86.9% of the patients suffered 
unbearable pain, versus 21.7% after one week, and a 
single patient after one month. The patients reported 
marked improvement  of the intensity of the attacks
(Fig. 1). After 12 months, 69.6% of the patients were 
free of pain, with or without medication; 17.4% showed 
clear improvement; and 13% experienced no significant 
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improvement. The duration of the outbreak was under 
10 days in 26% of the cases, 11-21 days in 17.3%, 21-40 
days in 13%, 41-60 days in 17.3%, and over 60 days in 
26%. None of the patients experienced adverse effects 
as a result of the medication provided. 
Discussion
Episodic cluster headache usually manifests in the sec-
ond or third decade of life, though it can also appear in 
older age groups. In effect, the literature describes cas-
es of first attacks of ECH manifesting within the 8-62 
years age range (12). In our study the mean patient age 
was 50.4 years (range 25-65). Regarding patient gender 
distribution, most of our patients were males, in coinci-
dence with the findings in the literature (12). However, 
according to Manzoni (13), the male predominance is 
gradually decreasing – possibly as a result of changes in 
lifestyle in both sexes, particularly in women (14). 
Many patients with cluster headache are wrongly di-
agnosed with symptomatic headache due to dental dis-
ease – this often leading to unnecessary and ineffective 
dental treatments (15). Bahra and Goadsby (16) found 
that 230 out of 511 patients had been examined by a 
dentist before being diagnosed with cluster headache. 
Leroux and Ducros (17) in turn found 16% of the pa-
tients to be subjected to dental or ocular treatment, or 
sinus surgery. In our series, 37.8% of the patients under-
went dental extractions in the affected quadrant after 
appearance of the pain, and posteriorly some of them 
requested even further dental treatments. In the study of 
Bittar and Graff-Radford (18), 14 out of 33 patients with 
cluster headache underwent some type of invasive and 
irreversible dental procedure. 
The pain is located in the periorbital and temporal area, 
extending to the ear and even to the occipital-cervical 
region (17). In the present study, the most common loca-
Clinical scale 
No. patients  
First visit 
No. patients 
First week 
No. patients 
1 month 
No. patients 
3 months 
No. patients 
6 months 
Total
patients
No pain - 5 9 15 15 16 
Mild - 2 3 3 3 2 
Bothersome - 7 4 1 2 2 
Moderate 3 4 6 2 1 - 
Important 12 4 - 1 1 2 
Terrible 8 1 1 1 1 1 
Table 2. Clinical scale assessing patient disability according to pain.
0
1
2
3
4
5
6
7
8
9
10
Firstvisit 1week 1month 3months 6months 12months
Fig. 1. Evolution of pain following the corticosteroid infiltrations. 
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tion was the region of the premolars and the periocular 
zone, in coincidence with the findings of most authors 
(15,19). This in turn led to dental extractions in 40% of 
the cases, in an attempt to resolve the pain, and extrac-
tions were even carried out in 37.8% of the cases after 
cluster headache had been diagnosed.
Most patients experience 1-3 attacks a day (19). Accord-
ing to Russell et al. (20), the total duration of the attacks 
was under one hour in 78% of the cases – this being 
similar to the duration recorded in our study (70.8%). 
Autonomic signs and symptoms are included among 
the diagnostic criteria of cluster headache (1). In this 
context, Nappi et al. (21) recorded vegetative manifes-
tations in 97% of all cases, while in our series 78% of 
the patients suffered such manifestations, which disap-
peared with resolution of the pain.
A variety of treatments have been investigated for pre-
vention or symptoms relief in these patients, including 
triptans (22,23), ergotamine (24), topiramate (8), hyper-
baric oxygen therapy (25), and oral or parenteral cor-
ticosteroids (10,26,27). Surgery must be viewed with 
great caution, since there are no reliable long-term data 
on the results obtained. In this context, different tech-
niques have been proposed, such as radiofrequency ab-
lation (28), rhizotomy of Gasser’s ganglion (29), greater 
occipital nerve block (9), and sphenopalatine ganglion 
block (3,4).
Mir et al. (27) administered 250 mg of methylpred-
nisolone as an intravenous bolus dose during three con-
secutive days, followed by 90 mg/day via the oral route 
for the next 10 days. With this treatment the attacks de-
creased significantly (p<0.05) compared with patients 
receiving other medications. In our study the infiltration 
of 40 mg of triamcinolone acetonide in the proximity of 
the sphenopalatine ganglion was found to be effective 
and safe, though in coincidence with other authors, the 
underlying mechanism of action is not clear (26).
According to Torelli and Manzoni (30), 85.7% of the 
patients exhibit a peak pain intensity score of between 
the 8 and 10 on the visual analog scale. In our study the 
mean pain score on the first visit was 8.8, and corticos-
teroid injection resulted in a reduction of the frequency 
and intensity of the attacks. On the first visit, 86.9% of 
the patients reported unbearable pain, versus 21.7% af-
ter one week, and a single patient after one month. No 
data for comparison are found in the literature. In any 
case, although it is very difficult to establish the natu-
ral course of patients with ECH, clear improvement was 
noted. It is difficult to establish a homogeneous sample, 
since the patients present subjective pain of different 
intensity and behavior over time. Controlled and rand-
omized studies are needed to firmly establish the role of 
corticosteroids administered in the vicinity of the sphe-
nopalatine ganglion in these patients.
The evolution of the patients with episodic cluster head-
ache is unpredictable and variable, though the admin-
istration of corticosteroids clearly reduced the duration 
and intensity of the pain attacks, and the duration of the 
outbreaks. 
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